IPP Bureau
GACL flags of first dispatch of Benzyl Alcohol and Benzaldehyde
By IPP Bureau - July 06, 2025
The facility will manufacture 13,200 MTPA Benzyl Chloride, 9,600 MTPA Benzyl Alcohol, and 7,200 MTPA Benzaldehyde
Shilpa Pharma Lifesciences Unit-1 inspected by ANVISA
By IPP Bureau - July 06, 2025
The audit has been concluded with no major observations
Suraksha Diagnostic unveils Eastern India's largest genomics lab
By IPP Bureau - July 06, 2025
Imfinzi approved in the EU as first and only perioperative immunotherapy for muscle-invasive bladder cancer
By IPP Bureau - July 06, 2025
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
European Commission fines Alchem for participating in API cartel
By IPP Bureau - July 05, 2025
The companies admitted taking part in the cartel in exchange for reduced fines but Alchem did not settle
Faron publishes study highlighting role of sClever-1 as immune blocker in cancer
By IPP Bureau - July 04, 2025
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
atai and Beckley Psytech announce positive Phase 2b results for treatment-resistant depression
By IPP Bureau - July 04, 2025
atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.
argenx advances clinical development of agonist antibody for myasthenic syndromes
By IPP Bureau - July 04, 2025
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
Sigachi updates on fire accident at its Pashamylaram Facility, Telangana
By IPP Bureau - July 04, 2025
The company has confirmed that the deceased are 39
Zota Health Care expands Davaindia network to 1,760 operational stores
By IPP Bureau - July 04, 2025
Surpassing 1,000 Company Owned Company Operated stores
Lupin launches nasal spray in US
By IPP Bureau - July 04, 2025
Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals
Alembic Pharmaceuticals acquires Utility Therapeutics for $12 million to strengthen US footprint
By IPP Bureau - July 03, 2025
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
Asahi Kasei Pharma starts Phase III study of promising CIPN prevention therapy
By IPP Bureau - July 03, 2025
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
WuXi XDC announces mechanical completion of Singapore site
By IPP Bureau - July 03, 2025
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
